Medicine Recommendations

Erectile Dysfunction - when supplied through Primary Care

Erectile Dysfunction - when supplied through Specialist Sexual Health Services

Benign Prostatic Hyperplasia (NICE TA273 - terminated appraisal)

NICE TA273 - Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia (terminated appraisal)

For treating premenopausal women at high risk of breast cancer unless they have a past history or may be at increased risk of thromboembolic disease or endometrial cancer.

Treatment of neuropathic pain in palliative care

Chronic severe pain in adults

Pain in the non-palliative care setting

Taurine deficiency in CF liver disease

Insomnia (short term use)

MHRA Drug Safety Update - Drugs and driving: blood concentration limits set for certain drugs

Secondary prevention of osteoporotic fragility fractures in postmenopausal women (NICE TA161)

NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women

Female sexual dysfunction following post oophorectomy or primary ovarian failure

Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests

As supplementation for menopausal women with low sexual desire if HRT alone is not effective.

For the treatment of trismus and mandibular hypomobility

Hypothyroidism

Prevention of atherothrombotic events after myocardial infarction in adults. (NICE TA420)

NICE TA420 - Ticagrelor for preventing atherothrombotic events after myocardial infarction

Acute Coronary Syndromes (NICE TA236)

NICE TA236 - Ticagrelor for the treatment of acute coronary syndromes

Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)

NICE TA575 - Tildrakizumab for treating moderate to severe plaque psoriasis

Asthma

COPD

MHRA Drug Safety Update - Tiotropium delivered via Respimat compared with Handihaler: no significant difference in mortality in TIOSPIR trial